AR028809A1 - Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica - Google Patents

Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica

Info

Publication number
AR028809A1
AR028809A1 ARP990106694A ARP990106694A AR028809A1 AR 028809 A1 AR028809 A1 AR 028809A1 AR P990106694 A ARP990106694 A AR P990106694A AR P990106694 A ARP990106694 A AR P990106694A AR 028809 A1 AR028809 A1 AR 028809A1
Authority
AR
Argentina
Prior art keywords
phase
days
conceptive
estrogen
effectively equivalent
Prior art date
Application number
ARP990106694A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22349144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR028809(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR028809A1 publication Critical patent/AR028809A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Método anticonceptivo que comprende administrar durante 21 días sucesivos a una mujer en sus anos fértiles, una combinacion de un estrogeno y un progestogeno en una dosis diaria anticonceptivamente eficaz en la cual existe una primera fase de 5-8 días en la cual la combinacion comprende un progestogeno equivalente efectivamente a aproximadamente 0,065 - 0,75 mg de noretindrona y un estrogeno equivalente efectivamente a aproximadamente 23 û 28 microng de etinil estradiol; seguido de una segunda fase de 7-11 días, donde la combinacion comprende un progestogeno equivalente efectivamente a aproximadamente de 0,25 - 1,0 mg de una noretindrona y un estrogeno equivalente efectivamente a aproximadamente a aproximadamente 23 - 28 microng de etinil estradiol; seguido por una tercera fase de 3 û-7 días donde la combinacion comprende un progestogeno equivalente efectivamente a aproximadamente 0,35 - 2,0 mg de noretindrona en combinacion con un estrogeno equivalente efectivamente a aproximadamente 23 - 28 mg de etinil estradiol; y seguido por 4 - 8 días que están libres de administracion de hormonas; con la condicion de que la dosis de progestina debería incrementarse desde la primera fase a la segunda fase hasta la tercera fase y que la dosis de estrogeno debe mantenerse constante en cada fase y una unidad anticonceptiva oral trifásica.
ARP990106694A 1998-12-23 1999-12-22 Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica AR028809A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11339498P 1998-12-23 1998-12-23
US09/328,764 US6214815B1 (en) 1998-12-23 1999-06-09 Triphasic oral contraceptive

Publications (1)

Publication Number Publication Date
AR028809A1 true AR028809A1 (es) 2003-05-28

Family

ID=22349144

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106694A AR028809A1 (es) 1998-12-23 1999-12-22 Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica

Country Status (26)

Country Link
US (2) US6214815B1 (es)
EP (1) EP1140109B1 (es)
JP (1) JP2002533398A (es)
KR (1) KR100669165B1 (es)
CN (1) CN100408040C (es)
AR (1) AR028809A1 (es)
AT (1) ATE318605T1 (es)
AU (1) AU765153B2 (es)
BR (1) BR9916579A (es)
CA (1) CA2356747C (es)
CY (1) CY1105276T1 (es)
CZ (1) CZ302568B6 (es)
DE (1) DE69930157T2 (es)
DK (1) DK1140109T3 (es)
ES (1) ES2259481T3 (es)
HU (1) HU229251B1 (es)
MX (1) MXPA01006533A (es)
NO (1) NO321118B1 (es)
NZ (1) NZ512404A (es)
PL (1) PL196715B1 (es)
PT (1) PT1140109E (es)
RU (1) RU2225207C2 (es)
SK (1) SK287931B6 (es)
TR (1) TR200101826T2 (es)
WO (1) WO2000038691A1 (es)
ZA (1) ZA200106006B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
HUP9900213A1 (hu) * 1999-02-01 2000-12-28 Gábor Bogye Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére
US20060281723A1 (en) * 1999-04-16 2006-12-14 Kafrissen Michael E Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
PT1390040E (pt) * 2001-05-18 2007-04-30 Pantarhei Bioscience Bv Composição farmacêutica para ser utilizado na terapia hormonal de substituição.
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US7871995B2 (en) * 2001-05-23 2011-01-18 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
CA2448271A1 (en) * 2001-05-23 2002-11-28 Panterhei Bioscience B.V. Means and method for hormonal contraception
DK1390042T3 (da) * 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
US8026228B2 (en) * 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
EP2305229A1 (en) 2001-12-05 2011-04-06 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
CA2489270C (en) * 2002-06-11 2012-08-07 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
CN1691947B (zh) * 2002-06-11 2011-11-23 潘塔希生物科学股份有限公司 雌激素成分在制备用于治疗或预防免疫介导的疾病中的应用以及包含所述雌激素成分的药物组合物
ES2299730T3 (es) * 2002-07-12 2008-06-01 Pantarhei Bioscience B.V. Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer.
JP2004140323A (ja) * 2002-08-20 2004-05-13 Sharp Corp 半導体レーザ装置およびその製造方法
WO2004037269A1 (en) * 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
WO2004098517A2 (en) 2003-05-02 2004-11-18 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
EP1648382A4 (en) * 2003-07-16 2009-09-16 Duramed Pharmaceuticals Inc HORMONE TREATMENT METHODS USING CONTRACEPTIVE DOSAGES WITH CONTINUOUS ADMINISTRATION OF ESTROGENES
US20050090475A1 (en) * 2003-10-01 2005-04-28 Laguardia Katherine D. Extended triphasic contraceptive regimens
DE102004026671A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP1814556A2 (en) * 2004-10-07 2007-08-08 Duramed Pharmaceuticals Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20070077269A1 (en) * 2005-10-04 2007-04-05 Woodward John R Method of birth control and hormone regulation
US20070254025A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
US20070254858A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
CN101583363B (zh) * 2007-01-08 2013-08-21 潘塔希生物科学股份有限公司 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
DE102007011486A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
WO2010042612A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
US9198876B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
WO2010111488A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
MX2017016823A (es) 2015-06-22 2018-03-12 Lipocine Inc Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3568828A (en) 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US3836651A (en) 1972-02-22 1974-09-17 Biolog Concepts Inc Novel oral contraceptive combination
DE2310963A1 (de) 1972-04-14 1974-09-05 Schering Ag Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten
US3969502A (en) 1972-04-14 1976-07-13 Schering Aktiengesellschaft Method for contraception by the administration of sequential contraceptive preparations
US3932635A (en) 1972-04-24 1976-01-13 Syntex Corporation Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
DE2365103C3 (de) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
US4291028A (en) 1977-12-30 1981-09-22 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
NL8001593A (nl) 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
USRE35724E (en) 1982-04-28 1998-02-03 Bio-Technology General Corp. Contraception system and method
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5276022A (en) 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US4948593A (en) 1989-05-15 1990-08-14 Alza Corporation Osmotic dosage form comprising an estrogen and a progestogen
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
US5453279A (en) 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5747480A (en) 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive

Also Published As

Publication number Publication date
KR20010081087A (ko) 2001-08-25
DK1140109T3 (da) 2006-05-15
KR100669165B1 (ko) 2007-01-17
RU2225207C2 (ru) 2004-03-10
MXPA01006533A (es) 2002-06-04
TR200101826T2 (tr) 2001-12-21
NO20013144D0 (no) 2001-06-22
CZ302568B6 (cs) 2011-07-13
SK8872001A3 (en) 2002-03-05
PT1140109E (pt) 2006-05-31
SK287931B6 (sk) 2012-04-03
AU1936500A (en) 2000-07-31
EP1140109A1 (en) 2001-10-10
JP2002533398A (ja) 2002-10-08
WO2000038691A1 (en) 2000-07-06
ATE318605T1 (de) 2006-03-15
US6214815B1 (en) 2001-04-10
EP1140109B1 (en) 2006-03-01
ZA200106006B (en) 2002-10-21
PL196715B1 (pl) 2008-01-31
DE69930157T2 (de) 2006-08-31
ES2259481T3 (es) 2006-10-01
CA2356747C (en) 2005-09-27
CA2356747A1 (en) 2000-07-06
CN1334734A (zh) 2002-02-06
NO20013144L (no) 2001-08-23
NO321118B1 (no) 2006-03-20
CN100408040C (zh) 2008-08-06
AU765153B2 (en) 2003-09-11
DE69930157D1 (de) 2006-04-27
CZ20012184A3 (cs) 2003-01-15
NZ512404A (en) 2003-08-29
HUP0104680A3 (en) 2002-06-28
US20010044429A1 (en) 2001-11-22
HU229251B1 (en) 2013-10-28
BR9916579A (pt) 2001-10-02
CY1105276T1 (el) 2010-03-03
HUP0104680A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
AR028809A1 (es) Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica
TR200200406T2 (tr) Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
NO982815D0 (no) Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkninsfullhet
DK0836506T4 (da) Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
DK365887D0 (da) Kombinationsdoseringsform til hormonbehandling af kvinder i prae-menopausen
KR890700349A (ko) 피임 및 유방암 억제용 조성물 및 이의 제조방법
TR200100234T2 (tr) Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması.
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
DK0917466T3 (da) Oralt antikonceptionsmiddel

Legal Events

Date Code Title Description
FB Suspension of granting procedure